AstraZeneca's COVID-19 antibody drug Evusheld maintained effectiveness against various omicron subvariants, including BA.2, in a recent independent laboratory study, the drugmaker said March 21.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,